Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BARBICAN: Ipatasertib + Atezolizumab + Chemotherapy in Neoadjuvant TNBC
NCT05498896Phase 2Active, not recruiting
- Sponsor
- Queen Mary University of London
- Start
- Dec 2018
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ipatasertib in triple-negative breast cancer (TNBC) (2 arms), sponsored by Queen Mary University of London. Primary endpoint: Pathological Complete Response at 6 months. Started Dec 2018; status: active, not recruiting.
02
Drugs
ipatasertib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05498896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05498896.